РусскийNo products in the cart.
Glucofage Long, 1000 mg 60 pcs
€14.84
Description
Type 2 diabetes
Type 2 diabetes mellitus in adults, especially in obese patients, when diet therapy and physical activity are ineffective:
as monotherapy;
in combination with other oral hypoglycemic agents or with insulin.
.
Active ingredient
Active ingredient
Metformin
Composition
Composition
1 tablet contains
The active ingredient:
metformin hydrochloride – 1000.0 mg;
Associates:
sodium carmellose – 50.0 mg, hypromellose 2208 – 392.3 mg, magnesium stearate – 7.0 mg.
How to take, the dosage
How to take, the dosage
The drug Glucofage® Long 1000 mg is taken orally. Tablets are swallowed whole, without chewing, with plenty of liquid, once a day during or after dinner. Dose of preparation Glucofazh® Long 1000 mg is individual for each patient based on the results of blood glucose concentration measurement.
Monotherapy and combined therapy in combination with other hypoglycemic agents
- Preparation Glucofazh® Long 1000 mg should be taken once a day during or after dinner.
- Glucofage® Long 1000 mg is indicated as maintenance therapy in patients who are taking metformin in the form of tablets with normal release in dose of 1000 mg or 2000 mg. To switch to Glucofage® Long 1000 mg, the daily dose should be equivalent to the daily dose of normal-release metformin.
- Patients taking metformin in the form of normal-release tablets at a dose greater than 2000 mg should not be recommended for switching to Glucofage® Long 1000 mg.
- For patients who do not take metformin, the recommended starting dose of Glucofage® Long is 500 mg or 750 mg once daily with supper (the following forms of release of Glucofage® Long are available: tablets with prolonged release 500 mg and 750 mg). Every 10-15 days it is recommended to adjust the dose on the basis of the results of blood glucose concentration measurement. Slowly increasing the dose promotes better tolerance from the gastrointestinal tract.
- In case of switching from another hypoglycemic drug, the dose is adjusted as described above, starting with Glucofage® Long 500 mg or 750 mg, with possible subsequent switching to Glucofage® Long 1000 mg.
Combination with insulin
To achieve better glycemic control
Interaction
Interaction
Contraindicated combinations
Iodine-containing radiopaque agents: Against the background of functional renal insufficiency in patients with diabetes mellitus, radiological examination with iodine-containing radiopaque agents may cause development of lactocidosis. Glucophage® Long should be discontinued depending on renal function 48 hours before or at the time of radiologic investigation with iodine-based radiopaque agents and should be restarted not earlier than 48 hours after, provided that renal function was considered normal at the time of investigation.
Do not recommend combinations
Alcohol: Acute alcohol intoxication increases the risk of lactoacidosis, especially in cases:
– undernutrition, adherence to a low-calorie diet;
– hepatic insufficiency.
Alcohol and medicinal products containing ethanol should be avoided while taking the drug.
Combinations requiring caution
Drugs with indirect hyperglycemic effects (e.g., glucocorticosteroids (GCS) and tetracosactide (systemic and topical), beta2-adrenomimetics, danazol, chlorpromazine when taken at high doses (100 mg daily) and diuretics): More frequent monitoring of blood glucose concentrations may be required, especially at the beginning of treatment. If necessary, the dose of Glucophage® Long may be adjusted during treatment and after discontinuation of treatment, based on the level of glycemia.
Diuretics: concomitant use of “loop” diuretics may lead to the development of lactoacidosis due to possible functional renal failure.
The concomitant use of Glucophage® Long with sulfonylurea derivatives, insulin, acarbose, salicylates may lead to hypoglycemia.
Nifedipine increases absorption and Cmax metformin. Cationic drugs (amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin) that are secreted in the renal tubules compete with metformin for tubular transport systems and may lead to an increase in its Cmax.
Colesevelam when used concomitantly with metformin in the form of sustained-release tablets increases plasma metformin concentrations (increased AUC without a significant increase in Cmax).
Special Instructions
Special Instructions
Lactoacidosis
Lactoacidosis is a rare but serious complication (high mortality in the absence of emergency treatment) that can occur due to metformin cumulation. Cases of lactoacidosis when taking metformin occurred mainly in patients with diabetes mellitus with severe renal insufficiency.
Synopsis
Synopsis
Prolonged tablets are white or almost white, capsule-shaped, biconvex, engraved “1000” on one side and “Megsk” on the other.
.
Contraindications
Contraindications
- High sensitivity to metformin or any excipient.
- Diabetic ketoacidosis, diabetic precoma, coma.
- Renal failure or renal function impairment (creatinine clearance <45 ml/min).
- Acute conditions with risk of renal dysfunction: dehydration (with chronic or severe diarrhea, repeated vomiting), severe infectious diseases (e.g., respiratory tract infections, urinary tract infections), shock.
- Chronic manifestations of acute or chronic diseases that may lead to the development of tissue hypoxia (including acute heart failure, chronic heart failure with unstable hemodynamic parameters, respiratory failure, acute myocardial infarction).
- Extensive surgical procedures and injuries when insulin therapy is indicated (see section “Special Precautions”).
- Hepatic failure, liver dysfunction.
- Chronic alcoholism, acute alcohol poisoning.
- Pregnancy.
- Lactoacidosis (including anamnesis).
- Application less than 48 hours before and 48 hours after radioisotopic or radiological studies with iodine-containing contrast media (e.g., intravenous urography, angiography) (see “Interaction with other alcohols”).
- Maintenance on a caloric restricted diet (<1000 kcal/d).
- Children under 18 years of age due to lack of data for use.
With caution
Consider the use of the drug:
- in patients over 60 years of age who perform heavy physical work, due to the increased risk of lactoacidosis in them;
- in patients with renal insufficiency (clearancecreatinine 45-59 ml/min)
- when breastfeeding.
.
Side effects
Side effects
The frequency of side effects of the drug is rated as follows:
Very frequent: ≥ 1/10
Frequent: ≥ 1/100, < 1/10
Infrequent: ≥ 1/1000, < 1/100
Rare: ≥ 1/10,000, < 1/1000
Very rare: ≤ 1/10,000
Overdose
Overdose
When using metformin at a dose of 85 g (42.5 times the maximum daily dose) the development of hypoglycemia was not observed. However, in this case the development of lactoacidosis was observed.
Similarities
Similarities
Siofor 500, Siofor 850, Metformin-Teva, Siofor 1000, Glucofage Long, Formetin, Metformin, Merifatin
Additional information
| Weight | 0.130 kg |
|---|---|
| Shelf life | 3 years. |
| Conditions of storage | Store at a temperature not exceeding 30 °C. |
| Manufacturer | Nanolek LLC, Russia |
| Medication form | sustained release tablets |
| Brand | Nanolek LLC |
Other forms…
Diabetes
€5.21
Diabetes
€8.32
Diabetes
€8.20
Diabetes
€11.30
Related products
Diabetes
€1.35
€46.07
Diabetes
€4.01
Diabetes
€5.24
Diabetes
€66.56
Diabetes
€13.17
Diabetes
€3.24
Buy Glucofage Long, 1000 mg 60 pcs with delivery to USA, UK, Europe and over 120 other countries.
